Globe Newswire
Tel Aviv, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company” or “ParaZero”), an aerospace company focused on drone safety systems for commercial drones and urban air mobility aircraft, today announced a strategic collaboration with Draganfly Inc. (Nasdaq: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly”), an industry pioneer in commercial drone technology, integrating its advanced safety technology into... (continue reading...)
Tel Aviv, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company” or “ParaZero”), an aerospace company focused on drone safety systems for commercial drones and urban air mobility aircraft, today announced a strategic collaboration with Draganfly Inc. (Nasdaq: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly”), an industry pioneer in commercial drone technology, integrating its advanced safety technology into... (continue reading...)
San Diego, CA., April 25, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., (NASDAQ: PRZO) a pioneer in drone safety systems aimed at enhancing the safety and efficacy of UAVs in medical and emergency response operations.
The integration of... (continue reading...)
Phosphorus brings its Mobile xIoT Security Lab and Gartner-recognized Unified xIoT Security Management Platform to RSAC to showcase its innovative new capabilities for IoT, OT, and IoMT discovery, remediation, and management.
NASHVILLE, Tenn., April 25, 2024 (GLOBE NEWSWIRE) -- Phosphorus Cybersecurity Inc., the leading provider of unified, prevention-based security management for the xTended Internet of Things (xIoT), is revealing groundbreaking new capabilities for... (continue reading...)
FORM 8.3
PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1.KEY INFORMATION (a)Full name of discloser:Invesco Ltd. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)Name of offeror/offeree in... (continue reading...)More Globe Newswire
View Older Stories-
EnviroGold Global to Build Demonstration Plant in Brisbane, Australia
-
Altisource Announces First Quarter 2024 Financial Results
-
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share
-
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
Valley National Bancorp Announces First Quarter 2024 Results
-
Xali Gold Announces a Modification to Deal Terms for SDA Plant in Mexico
-
Brunswick Exploration Drills 58.1 Meters at 1.59% Li2O Starting From Surface at Mirage
-
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
-
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
-
Microbix Collaborator Introduces New Lab Accreditation Program
-
DTE Energy reports first quarter earnings and accomplishments
-
First Northwest Bancorp Reports First Quarter 2024 Financial Results
-
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
-
Pool Corporation Reports First Quarter Results
-
IBN Coverage Initiated for Nutriband Inc.
-
Ultralife Corporation Reports First Quarter Results
-
Q Blockchain and Hyperlane Pioneer Cross-Chain Governance Solutions
-
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
-
Gov. Holcomb announces Amazon Web Services plans to invest $11B to create a new data center campus in Northern Indiana
-
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
-
Tecnoglass Sets Date for First Quarter 2024 Results
-
Nasdaq Reports First Quarter 2024 Results; Strong Execution Delivers Double-Digit Solutions Revenue Growth
-
PyroGenesis Announces Receipt of Two Separate Milestone Payments Totaling $970,000
-
Connectone Bancorp, Inc. Reports First Quarter 2024 Results; Declares Preferred and Increased Common Dividends
-
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
-
OTC Markets Group Welcomes Roth CH Acquisition Co. to OTCQX
-
Plug Signs Additional BEDP Contracts for a Total of 4.5GW of Electrolyzers Across Europe and the United States
-
Stericycle, Inc. Reports Results For The First Quarter 2024
-
American Airlines Reports First-Quarter 2024 Financial Results
-
Sandy Spring Bancorp Declares Quarterly Dividend
-
Sweetwater Brewing Unveils Modern Rebrand
-
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
-
Kirby Corporation Announces 2024 First Quarter Results
-
TELA Bio to Announce First Quarter 2024 Financial Results
-
“WORLD’S GREATEST AVIATION CELEBRATION” - EAA AIRVENTURE OSHKOSH - RETURNS JULY 22-28
-
Amwell to Participate in Upcoming Investor Conference
-
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
-
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
-
Climb Channel Solutions Launches Partnership with Automox, Providing Leading Endpoint Management Solution to North American Partners
-
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
-
New Benevity data shows companies that embrace an ‘impact mindset’ are building resilience in a polarized world
-
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
-
Wabash Recognizes Outstanding Suppliers for 2023
-
Garrett Motion Reports First Quarter 2024 Financial Results
-
ADT Reports First Quarter 2024 Results
-
Visteon Announces First Quarter 2024 Financial Results
-
Bread Financial™ Provides Performance Update for March 2024
-
Northrop Grumman Releases First Quarter 2024 Financial Results
-
Reliance, Inc. Reports First Quarter 2024 Financial Results